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Human cytomegalovirus (HCMV) is an important opportunistic pathogen in immunocompromised patients 
and a major cause of congenital birth defects when acquired in utero. In the 1990s, four chimeric viruses 
were constructed by replacing genome segments of the high passage Towne strain with segments of the low 
passage Toledo strain, with the goal of obtaining live attenuated vaccine candidates that remained safe but 
were more immunogenic than the overly attenuated Towne vaccine. The chimeras were found to be safe 
when administered to HCMV-seronegative human volunteers, but to differ significantly in their ability to 
induce seroconversion. This suggests that chimera-specific genetic differences impacted the ability to 
replicate or persist in vivo and the consequent ability to induce an antibody response. To identify specific 
genomic breakpoints between Towne and Toledo sequences and establish whether spontaneous mutations 
or rearrangements had occurred during construction of the chimeras, complete genome sequences were 
determined. No major deletions or rearrangements were observed, although a number of unanticipated 
mutations were identified. However, no clear association emerged between the genetic content of the 
chimeras and the reported levels of vaccine-induced HCMV-specific humoral or cellular immune responses, 
suggesting that multiple genetic determinants are likely to impact immunogenicity. In addition to revealing 
the genome organization of the four vaccine candidates, this study provided an opportunity to probe the 
genetics of HCMV attenuation in humans. The results may be valuable in the future design of safe live or 
replication-defective vaccines that optimize immunogenicity and efficacy. 
 
Human cytomegalovirus (HCMV) infections are an important cause of birth defects among newborns 
infected in utero and of morbidity and mortality in transplant and AIDS patients. Despite receiving the US 
IŶstitute of MediĐiŶe’s highest prioritǇ desigŶatioŶ iŶ ϮϬϬϬ [1], and after half a century of research, 
development of an HCMV vaccine remains an unmet medical need of considerable importance to public 
health.   
 
Among the first HCMV vaccine candidates was the live attenuated strain Towne vaccine produced by >125 
passages in cultured human fibroblasts [2]. This vaccine has been administered safely to nearly 1000 human 
subjects at doses as high as 3000 plaque-forming units (pfu), and has never been recovered from an 
immunized subject, even following immune suppression [3, 4, 5]. In contrast, the Toledo strain passaged only 
four or five times in cultured fibroblasts exhibited virulence characteristics in HCMV-seronegative volunteers 
at a dose of only 10 pfu [6], and was capable of superinfection, replicating, and persisting in the context of 
pre-existing natural immunity [6, 7]. Although administration of Towne vaccine prior to renal transplantation 
reduced post-transplant HCMV-associated disease, it did not prevent HCMV infections [3], and it failed to 
protect immunocompetent mothers from acquiring HCMV infections from their children [8]. These results 
suggest that the immunogenicity of the Towne vaccine may be overly attenuated due to mutations acquired 
during serial passage in vitro [9, 10, 11]. 
 
With the goal of increasing the immunogenicity of the Towne vaccine, four genetic chimeras were 
constructed by systematically replacing Towne genome segments with segments from Toledo [12]. Each 
chimera was shown to be safe when administered at a dose of 1000 pfu to healthy HCMV-seropositive 
human volunteers. However, failure to recover any chimera from blood, urine, or saliva following 
inoculation, combined with the inability of the chimeras to boost humoral or cellular immune responses, 
suggested that none retained the superinfection properties of the Toledo strain [12]. 
 
A phase 1 trial of the four chimeras in healthy HCMV-seronegative subjects was recently completed [13]. Each 
vaccine was administered to a total of nine subjects, with groups of three subjects receiving doses of 10, 
100, or 1000 pfu by the subcutaneous route. There were neither local nor systemic reactions nor serious 
adverse events, and none of the subjects shed infectious virus in urine or saliva. In general, cellular and 
humoral immune responses were comparable to those reported previously for the Towne vaccine, and none 
of the chimeras appeared to be more virulent or immunogenic than the Towne vaccine. However, with 
regard to seroconversion, chimeras 2 and 4 were clearly more immunogenic than chimeras 1 or 3: seven of 
the nine subjects who received chimera 4 seroconverted, as did three of the nine subjects who received 
chimera 2, while only one of the nine subjects who received chimera 1 seroconverted, and none of the nine 
subjects who received chimera 3 seroconverted [13]. 
 
These results suggest that genetic differences among the four chimeras significantly impacted their ability to 
replicate or persist in vivo to an extent necessary to induce an antibody response. Although the approximate 
locations of junctions between Towne and Toledo sequences in the chimeras have been reported [12], the 
precise breakpoints and any spontaneous mutations that may have arisen during recombinant virus 
construction were unknown. Therefore, we determined the complete sequences of all four chimeras. 
 
Table 1 summarizes genome information for the chimeras and complete (or substantially complete) Towne 
and Toledo sequences that were derived previously or during the present study. The Towne genomes 
represent two major variants, of which varS, in comparison with varL, has a large deletion at the right end of 
the UL region (commonly called UL/b′ [11]) associated with an inverted duplication of a sequence from the left 
end of UL [9]. Passage of HCMV in cell culture is known invariably to result in mutation of RL13 and also of 
UL128, UL130, or UL131A [14, 15, 16], the latter three genes encoding subunits of a pentameric complex 
necessary for efficient entry of HCMV into cells of the epithelial, endothelial, or myeloid lineages 
[17, 18, 19, 20, 21, 22]. Towne is mutated in RL13 and UL130, as well as in UL1, UL40, and US1 [9, 10], and the form of 
varS from which the chimeras were derived is also mutated in UL36 [23]. Toledo is mutated in RL13 and 
UL128 (the latter by the inversion of a large region of the genome) [11, 24, 25], as well as in UL9. Mapping the 
components of the chimeras was informed in particular by accessions FJ616285 and GQ121041 for Towne 
[9, 10] and accessions GU937742 and KY002201 for Toledo. GU937742 represents the standard form of Toledo 
from which the chimeras were derived (at passage 8), and KY002201 represents a variant (obtained via 
transfection of a Toledo DNA stock followed by plaque purification) that has a different mutation in gene 
RL13. The fact that more than one RL13 mutant was selected during isolation of Toledo is consistent with 
similar observations made with other strains, and indicates that adaptation of wild-type HCMV to cell 
culture involves a complex, gradual process of genetic selection [14, 15, 16]. Thus, both Towne and Toledo 
apparently carried mutations that had accumulated due to passage in fibroblasts. 
 
The genetic maps of the chimeras are shown in Fig. 1a. The parental strains are both nonepitheliotropic and 
nonendotheliotropic due to the mutations disrupting expression of UL130 (Towne) or UL128 (Toledo) 
[10, 17, 26]. The consequent failure to express a functional pentameric complex is speculated to contribute to 
attenuation of the Towne vaccine by limiting the range of host cell types available for replication in vivo, and 
to ToǁŶe’s iŶsuffiĐieŶt effiĐaĐǇ, as the peŶtaŵeriĐ Đoŵpleǆ is aŶ iŵportaŶt iŵŵuŶogeŶ for eliĐitiŶg 
antibodies that neutralize the entry of HCMV into cells of the epithelial, endothelial, and myeloid lineages 
[22, 27, 28, 29].   
 
By design [12], all four chimeras contain Toledo UL/b′ aŶd ǁithiŶ this a disrupted ĐopǇ of ULϭϮ8. Hoǁeǀer, 
prior to the present study, it was unclear whether chimeras 1 and 2 might contain an intact copy of UL128 
within the upstream Towne sequences, potentially rendering them epitheliotropic and endotheliotropic. 
However, as the sequence data indicate that Towne UL128 is absent from all four chimeras, none of them is 
genetically capable of expressing a functional UL128 protein or pentameric complex, even though the UL130 
and UL131A proteins, which contain neutralizing epitopes [30], may be expressed. Consistent with this, 
phenotypic analysis revealed that all four chimeras fail to enter ARPE-19 epithelial cells efficiently (Fig. 1b; 
[31]). By extension, the inability to express the pentameric complex is consistent with the phase 1 trial 
findings that the chimera vaccines induced neutralizing titers to entry into epithelial cells similar to those of 
Towne and significantly lower than those induced by natural infection [13]. In addition to the previously 
recognized mutations in the parental strains, the sequences revealed three novel mutations. The first 
disrupts UL147A in chimera 4, the second is a short duplication within the Towne-derived noncoding RNA4.9 
in chimeras 1, 3, and 4 (with two duplications in chimera 4), and the third is an intragenic deletion between 
US34A and TRS1 in chimera 1. A few other minor differences were also noted, as specified in the legend to 
Fig. 1. 
Examination of the mutations highlighted in Fig. 1a revealed no obvious association between the presence 
of particular mutations and the efficacy of the chimeras in inducing seroconversion. For example, the fact 
that chimeras 2 and 3 contain the same mutations except for one impacting UL40 might suggest that an 
inability to express UL40 renders chimera 3 unable to induce seroconversion. However, the same mutation 
is present in chimera 4, which is the most immunogenic of the vaccines. Indeed, each of the mutations 
present in chimera 3 is also present in immunogenic chimeras 2 or 4. Therefore, the ability to induce 
seroconversion is likely associated with the distribution of parental sequences among the chimeras rather 
than with specific mutations. For example, sequences from US16 to the right genome terminus are derived 
from Toledo in chimera 4 and from Towne in the other chimeras. This region contains immune evasion 
genes [32] and perhaps other elements that may contribute to the relatively enhanced immunogenicity of 
chimera 4. 
 
Although the phase 1 chimera trial did not include Towne vaccine, comparison to historical data suggested 
that all four chimeras are attenuated to a level similar to that of the Towne vaccine [13]. This indicates that 
the virulence characteristics associated with Toledo are multifactorial, in that none of the Toledo sequences 
appeared measurably to enhance virulence when inserted into the Towne genome. Alternatively, it is 
possible that the RL13 or UL128 mutations present in Toledo passage 8 and the chimeras did not fully 
pervade the viral population present in the Toledo passage 4 or 5 stocks that proved virulent in humans; 
that is, that some unmutated virus may have remained at this stage and was responsible for the biological 
effect. Unfortunately, Toledo passage 8 has not been tested in humans, and samples of earlier passages are 
no longer available. 
 
The construction and testing of the four chimeric vaccine candidates has provided a rare opportunity to 
study the genetics of viral pathogenesis in humans. While no specific virulence gene emerged from this 
limited study, the data suggest that relatively few genetic changes are capable of producing a virus that is 
highly attenuated and yet capable of replicating in vivo to an extent required to induce both humoral and 
cellular immune responses. These findings may be valuable for rationally designing live attenuated or 
replication-defective vaccines that maximize safety while optimizing immunogenicity and efficacy. 
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Table 1 
 
Strain Genome Accession Size (bp) Release date Reference 
Towne BAC varS AC146851 229,483 14-Oct-2003 (33) 
Towne BAC varS AY315197 222,047 01-Dec-2003 (34) 
Towne Virus varL FJ616285 235,147 07-Feb-2009 (9) 
Towne BAC varL GQ121041 238,311 17-Jun-2009 (10) 
Towne BAC mutant (UL96) varS KF493877 233,028 18-Aug-2013 (35) 
Towne Virus mutant (UL96) varS KF493876 232,948 18-Aug-2013 (36) 
Toledo BAC AC146905 226,889 21-Oct-2003 (33) 
Toledo Virus AH013698 158,133 08-Mar-2004 (36) 
Toledo Virus GU937742 235,404 10-Mar-2010 Present work 
Toledo Virus variant KY002201 235,681 15-Nov-2016 Present work 
Toledo Virus mutant (RNA2.7) KY002200 233,779 15-Nov-2016 Present work 
Towne/Toledo Virus chimera 1 KX101021 235,882 08-Jun-2016 Present work 
Towne/Toledo Virus chimera 2 KX101022 234,441 08-Jun-2016 Present work 
Towne/Toledo Virus chimera 3 KX101023 235,354 08-Jun-2016 Present work 
Towne/Toledo Virus chimera 4 KX101024 236,269 08-Jun-2016 Present work 
 
Genomes were sequenced as bacterial artificial chromosomes (BACs), viruses, virus variants, virus mutants, or virus chimeras, 
and in varS or varL form for Towne. The two Towne BAC varS sequences describe the same BAC but differ in size because they 
lack different parts of the vector. The chimeras that had been used to inoculate seronegative human subjects [13] were amplified 
by passaging twice in MRC-5 human fibroblast cells, and virion DNA was isolated from culture supernatants as described 
previously [37]. Sequence data were obtained for these and the other viruses examined in the present work using the Illumina 
MiSeq platform, and assembled and validated as described previously [38]. Additional information is available in the GenBank 
accessions 
 
 
 
 
 
  
Figure 1 
 
 
 
a Sequence-based genetic maps of the four Towne/Toledo chimera vaccine strains. Open arrows indicate open reading 
frames, and lines with arrowheads indicate noncoding RNAs. Tall rectangles indicate inverted repeats (a/a′ and c/c′), and 
these and other features (oriLyt, RNA4.9, IRS1, and TRS1) are labeled on chimera 1. Genes containing disrupting 
mutations are labeled in red, and genes located at breakpoints are labeled in black (these include UL36 in chimera 2). 
Additional differences among regions derived from the same original strain are not marked. These include a large 
noncoding deletion between US34A and TRS1 in chimera 2, a small noncoding deletion between UL150A and IRS1 in 
chimera 3, a short region of Towne sequence at the beginning of the Toledo a′ sequence in chimera 2 (probably as a 
result of recombination), a few differences in the lengths of noncoding G:C tracts, three substitutions in intergenic regions 
(UL102/UL103 and UL124/UL128 in chimera 1, and UL23/UL24 in chimera 4), one substitution in RNA5.0 in chimera 2, 
two synonymous substitutions in coding regions (UL10 and TRS1 in chimera 1), four nonsynonymous substitutions 
(UL11 and US10 in chimera 1, UL47 in chimera 2, and UL93 in chimera 4), and a small number (2–6 per genome) of 
nucleotide polymorphisms. The recombinational breakpoints in US16 in chimeras 1, 2, and 3 are located within a 255  bp 
sequence that is identical in Towne and Toledo. The values on the right indicate the relative immunogenicity levels of 
each chimera reported previously [13].  
 
b MRC-5 fibroblast or ARPE-19 epithelial cells were mock-infected or infected with equivalent amounts of the indicated 
viruses and after 4 d stained for HCMV immediate early proteins as described previously [27]. BADrUL131 and TS15-rN 
are epitheliotropic variants of HCMV strains AD169 and Towne varS, respectively [26, 39], and TS15 is a nonepitheliotropic 
variant of Towne varS [10] (Colour figure online) 
 
 
 
